CN114502552B - 哒嗪酮trpc抑制剂的晶体形式 - Google Patents

哒嗪酮trpc抑制剂的晶体形式 Download PDF

Info

Publication number
CN114502552B
CN114502552B CN202080042302.9A CN202080042302A CN114502552B CN 114502552 B CN114502552 B CN 114502552B CN 202080042302 A CN202080042302 A CN 202080042302A CN 114502552 B CN114502552 B CN 114502552B
Authority
CN
China
Prior art keywords
crystalline form
disease
pharmaceutical composition
dihydropyrido
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080042302.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114502552A (zh
Inventor
高岳君
薛文峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GFB(ABC) Limited Liability Company
Original Assignee
Goldfinch Biology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Biology Co filed Critical Goldfinch Biology Co
Priority to CN202411019840.2A priority Critical patent/CN119264134A/zh
Publication of CN114502552A publication Critical patent/CN114502552A/zh
Application granted granted Critical
Publication of CN114502552B publication Critical patent/CN114502552B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202080042302.9A 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式 Active CN114502552B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411019840.2A CN119264134A (zh) 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081985 2019-04-10
PCT/CN2019/081985 WO2020206623A1 (en) 2019-04-10 2019-04-10 Crystal forms
PCT/US2020/027689 WO2020210639A1 (en) 2019-04-10 2020-04-10 Crystal forms of a pyridazinone trpc inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411019840.2A Division CN119264134A (zh) 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式

Publications (2)

Publication Number Publication Date
CN114502552A CN114502552A (zh) 2022-05-13
CN114502552B true CN114502552B (zh) 2024-08-16

Family

ID=70482847

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080042302.9A Active CN114502552B (zh) 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式
CN202411019840.2A Pending CN119264134A (zh) 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411019840.2A Pending CN119264134A (zh) 2019-04-10 2020-04-10 哒嗪酮trpc抑制剂的晶体形式

Country Status (10)

Country Link
US (1) US12655132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953352A1 (cg-RX-API-DMAC7.html)
JP (2) JP7738482B2 (cg-RX-API-DMAC7.html)
CN (2) CN114502552B (cg-RX-API-DMAC7.html)
AU (2) AU2020272030C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018221A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136652A1 (cg-RX-API-DMAC7.html)
MA (1) MA55614A (cg-RX-API-DMAC7.html)
MX (2) MX2021012313A (cg-RX-API-DMAC7.html)
WO (2) WO2020206623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
LT3852533T (lt) * 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP7701559B2 (ja) * 2021-09-10 2025-07-01 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
EP4470540A4 (en) * 2022-01-27 2025-06-11 Wuhan Createrna Science and Technology Co.,Ltd. USE OF A HETEROCYCLIC COMPOUND
CN119546303A (zh) * 2022-08-05 2025-02-28 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
WO2020061162A1 (en) * 2018-09-18 2020-03-26 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
KR102873922B1 (ko) 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
WO2020061162A1 (en) * 2018-09-18 2020-03-26 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof

Also Published As

Publication number Publication date
JP7738482B2 (ja) 2025-09-12
EP3953352A1 (en) 2022-02-16
CA3136652A1 (en) 2020-10-15
WO2020206623A1 (en) 2020-10-15
BR112021018221A2 (pt) 2022-01-18
MX2021012313A (es) 2021-11-17
JP2022525759A (ja) 2022-05-19
MA55614A (fr) 2022-02-16
JP2026004294A (ja) 2026-01-14
MX2025006384A (es) 2025-07-01
AU2020272030C1 (en) 2026-05-07
US20220177455A1 (en) 2022-06-09
AU2020272030B2 (en) 2025-11-13
WO2020210639A1 (en) 2020-10-15
AU2026201003A1 (en) 2026-03-05
CN114502552A (zh) 2022-05-13
AU2020272030A1 (en) 2021-11-11
CN119264134A (zh) 2025-01-07
US12655132B2 (en) 2026-06-16

Similar Documents

Publication Publication Date Title
AU2020272030C1 (en) Crystal forms of a pyridazinone TRPC inhibitor
CN114040913B (zh) 哒嗪酮trpc5抑制剂的喷雾干燥制剂
US8673864B2 (en) Mangiferin-berberine salt, manufacturing method and use thereof
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20100247517A1 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
US20240091303A1 (en) Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
US20120149685A1 (en) Composition and method for the treatment of tauopathies
WO2026067059A1 (zh) Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途
JP2004534760A (ja) 腎線維症の治療
HK40122791A (en) Crystal forms of a pyridazinone trpc inhibitor
KR102057441B1 (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
BR122025019562A2 (pt) Formas cristalinas de um inibidor de trpc de piridazinona, composição farmacêutica que as compreende e uso das mesmas
WO2012060308A1 (ja) 腎機能障害の予防又は治療に用いる医薬
US20100099719A1 (en) Composition and method for treating proteinuria
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão
WO2023066127A1 (zh) 速激肽受体3抑制剂的用途
US8318743B2 (en) Medicament for the enhancement of cognitive function and neuroprotection
TW200522962A (en) Neutrophilia inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260428

Address after: Massachusetts, USA

Patentee after: GFB(ABC) Limited Liability Company

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Goldfinch biology Co.

Country or region before: U.S.A.

TR01 Transfer of patent right